CD274 and alveolar soft part sarcoma: Tan et al. reported a study with 29 patients with advanced alveolar soft part sarcoma (ASPS) treated with anlotinib, a widely used TKI in China, and TQB2450, a PD-L1 inhibitor, with an ORR of 79.3% [41].